All In Biotech

Drug Trial Radar · NCT07336732

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

An Open-label, Randomized, Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harboring Atypical EGFR Mutations Who Have Not Received Prior Systematic Therapy

Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Mar 11, 2026

Primary completion

Nov 2026

Study completion Jan 2029

Sponsor

Sponsor type
Industry
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, randomized, multicenter phase II/III clinical trial designed to evaluate the efficacy, safety, and tolerability of Andamertinib with or without platinum-based chemothsrapy versus platinum-based chemotherapy in previously untreated participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR atypical mutations. The study comprises two stages: phase II (dose-exploration stage) and phase III (pivotal study stage)

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

  • PLB1004Drug

    Andamertinib with or without platinum-based chemothsrapy versus platinum-based chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).Time frame: Up to 3 years
  2. RP3D or recommended phase 3 treatment regimenTime frame: Up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-Sen University Cancer Center

    Guangzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.